Xiang L, Li X, Luo Y, Zhou B, Liu Y, Li Y
Life Metab. 2025; 1(3):242-257.
PMID: 39872077
PMC: 11749464.
DOI: 10.1093/lifemeta/loac034.
Hosseini Shabanan S, Martins V, Wolfson T, Weeks J, Ceriani L, Behling C
Radiographics. 2024; 44(11):e240048.
PMID: 39418184
PMC: 11580021.
DOI: 10.1148/rg.240048.
Pierce T, Ozturk A, Sherlock S, Moura Cunha G, Wang X, Li Q
Radiology. 2024; 312(3):e233094.
PMID: 39254458
PMC: 11427856.
DOI: 10.1148/radiol.233094.
Rauzier C, Chartrand D, Almeras N, Lemieux I, Larose E, Mathieu P
Diabetes Metab Syndr Obes. 2024; 17:3335-3341.
PMID: 39252871
PMC: 11382664.
DOI: 10.2147/DMSO.S466051.
Zannad F, Sanyal A, Butler J, Miller V, Harrison S
Nat Med. 2024; 30(9):2423-2431.
PMID: 39227442
DOI: 10.1038/s41591-024-03223-z.
Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery.
Herrera-Marcos L, Arbones-Mainar J, Osada J
Int J Mol Sci. 2024; 25(15).
PMID: 39125855
PMC: 11311740.
DOI: 10.3390/ijms25158285.
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
Anstee Q, Magnanensi J, Hajji Y, Caron A, Majd Z, Rosenquist C
JHEP Rep. 2024; 6(4):101011.
PMID: 38463540
PMC: 10920708.
DOI: 10.1016/j.jhepr.2024.101011.
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information.
McTeer M, Applegate D, Mesenbrink P, Ratziu V, Schattenberg J, Bugianesi E
PLoS One. 2024; 19(2):e0299487.
PMID: 38421999
PMC: 10903803.
DOI: 10.1371/journal.pone.0299487.
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease.
Ramos M, Kendall T, Drozdov I, Fallowfield J
Ann Hepatol. 2023; 29(2):101278.
PMID: 38135251
PMC: 10907333.
DOI: 10.1016/j.aohep.2023.101278.
From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease.
Rinella M, Sookoian S
J Lipid Res. 2023; 65(1):100485.
PMID: 38103785
PMC: 10824973.
DOI: 10.1016/j.jlr.2023.100485.
The Future Is Beyond Bright: The Evolving Role of Quantitative US for Fatty Liver Disease.
Ozturk A, Kumar V, Pierce T, Li Q, Baikpour M, Rosado-Mendez I
Radiology. 2023; 309(2):e223146.
PMID: 37934095
PMC: 10695672.
DOI: 10.1148/radiol.223146.
Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium.
Fowler K, Venkatesh S, Obuchowski N, Middleton M, Chen J, Pepin K
Radiology. 2023; 309(1):e231092.
PMID: 37815451
PMC: 10625902.
DOI: 10.1148/radiol.231092.
Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH).
Wang S, Friedman S
Sci Transl Med. 2023; 15(716):eadi0759.
PMID: 37792957
PMC: 10671253.
DOI: 10.1126/scitranslmed.adi0759.
NAFLD: Diagnostics and New Nomenclature.
Kanagalingam G, Sanyal A
J Clin Exp Hepatol. 2023; 13(5):723-724.
PMID: 37693255
PMC: 10482989.
DOI: 10.1016/j.jceh.2023.07.003.
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis.
Sanyal A, Shankar S, Yates K, Bolognese J, Daly E, Dehn C
Nat Med. 2023; 29(10):2656-2664.
PMID: 37679433
PMC: 10579051.
DOI: 10.1038/s41591-023-02539-6.
Tailored Chemical Reactivity Probes for Systemic Imaging of Aldehydes in Fibroproliferative Diseases.
Ma H, Zhou I, Chen Y, Rotile N, Ay I, Akam E
J Am Chem Soc. 2023; 145(38):20825-20836.
PMID: 37589185
PMC: 11022681.
DOI: 10.1021/jacs.3c04964.
The current status of imaging in liver fibrosis.
Fowler K, Bashir M
Nat Rev Gastroenterol Hepatol. 2023; 20(10):628-629.
PMID: 37537333
DOI: 10.1038/s41575-023-00833-9.
The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis.
Sanyal A, Shankar S, Yates K, Bolognese J, Daly E, Dehn C
Res Sq. 2023; .
PMID: 36711803
PMC: 9882658.
DOI: 10.21203/rs.3.rs-2492725/v1.
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Sanyal A, Williams S, Lavine J, Neuschwander-Tetri B, Alexander L, Ostroff R
J Hepatol. 2022; 78(4):693-703.
PMID: 36528237
PMC: 10165617.
DOI: 10.1016/j.jhep.2022.11.029.
Magnetic resonance imaging proton density fat fraction as an imaging-based biomarker of treatment response in patients with nonalcoholic steatohepatitis.
Stine J, Loomba R
Clin Liver Dis (Hoboken). 2022; 20(6):198-201.
PMID: 36523866
PMC: 9745255.
DOI: 10.1002/cld.1249.
